drugset / Trial / NCT00100074

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074

Phase 1 Unknown 8 enrolled National Institute on Drug Abuse (NIDA)
Diagnostic

Summary

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Timeline

Start
2004-09
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeline Small molecule 7.5 mg
Subject Lobeline Small molecule 15 mg
Subject Lobeline Small molecule 30 mg